Generic Name and Formulations:
Triamcinolone acetonide 40mg/mL; susp for intravitreal inj.
Alcon Laboratories, Inc.
Indications for TRIESENCE:
Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Visualization during vitrectomy.
Adults and Children:
Give anesthesia and broad-spectrum microbicide prior to use. Ophthalmic diseases: initially 4mg (100microliters); may repeat if needed. Visualization: 1–4mg (25–100microliters) intravitreally.
Systemic fungal infections. Live vaccination.
Not for IV administration. Ocular herpes simplex. Cerebral malaria: not recommended. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Strongyloides infestation. Latent amebiasis. Thyroid disorders. Diabetes. CHF. Hypertension. Recent MI. Renal insufficiency. GI perforation. Diverticulitis. Intestinal anastomoses. Peptic ulcer. Myasthenia gravis. Hypoprothrombinemia. Monitor for osteoporosis (esp. postmenopausal women) if on long-term therapy; do bone density tests. Supplement with additional steroids in physiologic stress. Monitor growth, weight, blood pressure, fluid and electrolyte balance. Avoid abrupt cessation. Pregnancy (Cat.D); (avoid in 1st trimester). Nursing mothers.
Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), ephedrine, cholestyramine. May potentiate cyclosporine. May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin, other NSAIDs. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Withdraw anticholinesterase agents at least 24 hours before starting corticosteroid therapy. May suppress reactions to skin tests.
Elevated intraocular pressure (monitor), cataracts, endophthalmitis, hypopyon, inj site reactions, glaucoma, vitreous floaters, retinal pigment epithelium detachment, optic disc vascular disorder, eye inflammation, conjunctival hemorrhage, reduced visual acuity, HPA axis suppression, masks infection, increased susceptibility to infection, hypertension, hypokalemia, weight gain, osteoporosis, behavioral or mood disturbances, myopathy, Kaposi's sarcoma.
Single-use vial (1mL)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders